Maintaining Life-saving Testing for Patients With Infectious Diseases: Infectious Diseases Society of America, American Society for Microbiology, and Pan American Society for Clinical Virology Recommendations on the Regulation of Laboratory-developed Tests

In 2014, the US Food and Drug Administration (FDA) proposed to regulate laboratory-developed tests (LDTs)—diagnostics designed, manufactured, and used within a single laboratory. The Infectious Diseases Society of America, the American Society for Microbiology, and the Pan American Society for Clinical Virology recognize that the FDA is committed to protecting patients. However, our societies are concerned that the proposed regulations will limit access to testing and negatively impact infectious diseases (ID) LDTs. In this joint commentary, our societies discuss why LDTs are critical for ID patient care, hospital infection control, and public health responses. We also highlight how the FDA's proposed regulation of LDTs could impair patient access to life-saving tests and stifle innovation in ID diagnostics. Finally, our societies make specific recommendations for the FDA's consideration to reduce the burden of the proposed new rules on clinical laboratories and protect patients' access to state-of-the art, quality LDTs.

Source: Clinical Infectious Diseases - June 29, 2016 Category: Infectious Diseases Authors: Caliendo, A. M., Couturier, M. R., Ginocchio, C. C., Hanson, K. E., Miller, M. B., Walker, K. E., Frank, G. M., for the Infectious Diseases Society of America; the American Society for Microbiology; and the Pan-American Society for Clinical Virology Tags: IDSA PUBLIC POLICY Source Type: research